JAMA,
In patients with moderately to severely active ulcerative colitis, risankizumab improved the rates of clinical remission when…
Risankizumab for Ulcerative Colitis
Overview of attention for article published in JAMA: Journal of the American Medical Association, September 2024
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (99th percentile)
-
High Attention Score compared to outputs of the same age and source (88th percentile)
Mentioned by
- news
- 23 news outlets
- blogs
- 1 blog
- 65 X users
- patent
- 2 patents
- 1 Facebook page
- 1 Redditor
- video
- 1 YouTube creator
- guideline
- 3 clinical guideline sources
- podcasts
- 1 podcast
Readers on
- mendeley
- 106 Mendeley